Correction: BMC Public Health 23, 859 (2023)

https://doi.org/10.1186/s12889-023-15749-x

The original publication of this article [1] contained several transcription errors as a result of importing data from the statistical software. The correct data calculation was used for the results & conclusions of the paper. The incorrect & correct information is listed in this correction article, the original article has been updated.

Section

Incorrect

Correct

Results

Finally, 372 articles were included: 352 studies

for prevalence analysis, 7 for incidence analysis, and

114 for outcome analysis (some studies provided data on

prevalence, incidence and/or outcomes at the same time;

hence, the total number was different from the sum of

subgroups) (Fig. 1)

Finally, 372 articles were included: 353 studies

for prevalence analysis, 7 for incidence analysis, and

114 for outcome analysis (some studies provided data on

prevalence, incidence and/or outcomes at the same time;

hence, the total number was different from the sum of

subgroups) (Fig. 1)

The prevalence rates

were relatively low in Sichuan (1.8%, 95% CI: 1.1–2.6),

Beijing (1.9%, 95% CI: 0.1–2.6), Guangdong (1.9%, 95%

CI: 0.7–3.6), Jiangsu (2.2%, 95% CI: 1.9–2.5), and Shanghai

(2.9%, 95% CI: 2.5–3.3), all which were relatively economically

developed regions (Table 1)

The prevalence rates

were relatively low in Sichuan (1.8%, 95% CI: 1.1–2.6),

Beijing (1.9%, 95% CI: 0.1–5.5), Guangdong (1.9%, 95%

CI: 0.7–3.6), Jiangsu (2.2%, 95% CI: 1.9–2.5), and Shanghai

(2.9%, 95% CI: 2.5–3.3), all which were relatively economically

developed regions (Table 1)

Herein, 62 studies [14–16, 18–20, 22–25, 29–31, 33–

40, 44–46, 50, 53, 55, 56, 58–60, 63–67, 71, 77, 78, 80,

81, 84–86, 92, 93, 96, 97, 99–101, 104–107, 111] were

included to analyze the influence of sex on the prevalence

of ARLD. The prevalence of male was 2.9% (95% CI: 2.4–

3.5), which was much higher than that of women (0.5%,

95% CI: 0.4–0.7) (Table 1)

Herein, 58 studies [14–16, 18–20, 22–25, 29–31, 33–

40, 44–46, 50, 53, 55, 56, 58–60, 63–67, 71, 77, 78, 80,

81, 84–86, 92, 93, 96, 97, 99–101, 104–107, 111] were

included to analyze the influence of sex on the prevalence

of ARLD. The prevalence of male was 2.9% (95% CI: 2.4–

3.5), which was much higher than that of women (0.5%,

95% CI: 0.4–0.7) (Table 1)

Three of

the 69 articles [210, 235, 236] described that the liver

damage caused by concurrent hepatitis virus infection

and alcohol was severe

Three of

the 67 articles [210, 235, 236] described that the liver

damage caused by concurrent hepatitis virus infection

and alcohol was severe

A total of 121 datasets [25, 26, 30, 43,

47, 113, 115, 116, 122, 125, 126, 128, 129, 131, 132, 136,

137, 142, 153, 156, 157, 161, 162, 168, 171–173, 176, 178,

186, 190, 193–197, 204, 207, 208, 213, 215, 221, 225–230,

241–243, 245, 250–252, 255, 262, 267, 272, 275, 276,

294, 297, 299, 306, 311, 318, 321–372] were used to analyze

the prevalence of ascites, gastrointestinal bleeding,

hepatic encephalopathy, spontaneous peritonitis (SBP),

hepatorenal syndrome, and bacterial infection in ARLD

A total of 119 datasets [25, 26, 30, 43,

47, 113, 115, 116, 122, 125, 126, 128, 129, 131, 132, 136,

137, 142, 153, 156, 157, 161, 162, 168, 171–173, 176, 178,

186, 190, 193–197, 204, 207, 208, 213, 215, 221, 225–230,

241–243, 245, 250–252, 255, 262, 267, 272, 275, 276,

294, 297, 299, 306, 311, 318, 321–372] were used to analyze

the prevalence of ascites, gastrointestinal bleeding,

hepatic encephalopathy, spontaneous peritonitis (SBP),

hepatorenal syndrome, and bacterial infection in ARLD

Table 1

5.0% (4.3–5.8)

4.8%(4.1–5.6)

Table 2

69

67

Figure 2 caption

The global prevalence of ARLD. The prevalence in 14 countries was indicated by depth of red. The 15 countries included Portugal, Canada,

Iceland, France, China, USA, Denmark, South Korea, Uganda, India, UK, Sweden, Japan, and Italy

The global prevalence of ARLD. The prevalence in 14 countries was indicated by depth of red. The 14 countries included Portugal, Canada,

Iceland, France, China, USA, Denmark, South Korea, Uganda, India, UK, Sweden, Japan, and Italy

Figure 3 caption

The prevalence of ARLD in China by provinces. The prevalence in 21 provinces of China was indicated by depth of red. The prevalence in

China was obtained from the analysis of 19 cities or provinces including Sichuan, Beijing, Guangdong, Jiangsu, Shanghai, Gansu, Shaanxi, Guizhou,

Zhejiang, Henan, Hunan, Jilin, Heilongjiang, Taiwan, Tibet, Liaoning, Yunnan, Anhui, Shandong, Hebei, and Xinjiang provinces

The prevalence of ARLD in China by provinces. The prevalence in 21 provinces of China was indicated by depth of red. The prevalence in

China was obtained from the analysis of 21 cities or provinces including Sichuan, Beijing, Guangdong, Jiangsu, Shanghai, Gansu, Shaanxi, Guizhou,

Zhejiang, Henan, Hunan, Jilin, Heilongjiang, Taiwan, Tibet, Liaoning, Yunnan, Anhui, Shandong, Hebei, and Xinjiang provinces

Discussion

Taken together, these results showed that ARLD is one

of the most common chronic liver diseases in the world,

with a prevalence of 5.8%

Taken together, these results showed that ARLD is one

of the most common chronic liver diseases in the world,

with a prevalence of 4.8%